FDA recall, , Moderate risk
Alvogen Levothyroxine Sodium Tablets Thy-Tabs
Levothyroxine Sodium Tablets, USP, Thyro-Tabs may contain 88 mcg tablets instead of 150 mcg tablets.
Summary by Recall Canary from the FDA notice
What happened
Alvogen, Inc., of Morristown, New Jersey, recalled Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, distributed nationwide, after a pharmacy reported that a single bottle of this lot contained 88 mcg tablets instead of 150 mcg tablets. The recall began on December 31, 2025, and was added to the FDA's Enforcement Report on January 14, 2026.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
- NDC
- 47781-662-10
- Lot code
- MHA21825
Recall details
- Company began the recall
- Sold in
US Nationwide.
- Company
- Alvogen, IncMorristown, New Jersey
- Hazard
- Labeling error
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98225
- Recall number
- D-0259-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
In FDA's weekly enforcement report
Listed on Recall Canary
